Pharmaceuticals, Biotechnology and Life Sciences
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive …
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive …
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive …
DUBLIN–(BUSINESS WIRE)–The “Global Healthcare Contract Development & Manufacturing Organization Market (2020-2025) by services Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMa…
DUBLIN–(BUSINESS WIRE)–The “Global Healthcare Contract Development & Manufacturing Organization Market (2020-2025) by services Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMa…
First Compound to Enter Clinical Trial from CANbridge Rare Disease Strategic Partnership with WuXi Biologics
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing inno…
First Compound to Enter Clinical Trial from CANbridge Rare Disease Strategic Partnership with WuXi Biologics
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing inno…
First Compound to Enter Clinical Trial from CANbridge Rare Disease Strategic Partnership with WuXi Biologics
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing inno…
First Compound to Enter Clinical Trial from CANbridge Rare Disease Strategic Partnership with WuXi Biologics
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing inno…
First Compound to Enter Clinical Trial from CANbridge Rare Disease Strategic Partnership with WuXi Biologics
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing inno…